Clinical trials: Nut Allergy
Peanut Allergy
Xolair Enhances Oral Desensitization in Peanut Allergic Patients
This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.
- Trial name
- NCT01290913
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Lynda Schneider
Nut Hypersensitivity, Child
Phenotypical Characterization of Peanut Allergic Children
Peanut allergy (PA) has been well studied and its prevalence was estimated up to 1.3% in Europe. Tree nut (TN) allergy and PA are clinically similar and often coexist, TN allergy prevalence ranged from 0.05 to 4.9 %.
- Conditions
- Nut Hypersensitivity, Child, Legumes Allergy, Tree Nut Allergy
- Trial name
- NCT02961452
- Testing
- Cross reaction detection
- Volunteers
- 317 people
- Sponsor
- Lille Catholic University
Peanut Allergy
Study of Tolerance to Oral Peanut
Open pilot study of peanut oral immunotherapy in 22 children with peanut allergy
- Trial name
- STOP (NCT01259804)
- Testing
- Peanut oral immunotherapy
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Food Allergy, Food Allergy Peanut
Preventing Anaphylaxis With Acalabrutinib
Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis.
- Trial name
- NCT05038904
- Testing
- Acalabrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Peanut Allergy
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
The objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize…
- Trial name
- VIPES (NCT01675882)
- Testing
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- DBV Technologies
Peanut Allergy
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.
- Trial name
- NCT05424731
- Testing
- DBV712 250 mcg
- Where
- United States
- Sponsor
- DBV Technologies
Peanut Allergy
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
Severe peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today.
- Trial name
- FASTX (NCT02402231)
- Testing
- Omalizumab
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- Caroline Nilsson
IgE-Mediated Food Allergy, Peanut Allergy
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin…
- Conditions
- IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
- Trial name
- NCT07768371
- Testing
- Remibrutinib
- Where
- 18 sites in United States
- Volunteers
- 576 people
- Sponsor
- Novartis Pharmaceuticals
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Food Allergy
Trichuris Suis Ova in Peanut and Tree Nut Allergy
The goal of this study is to determine whether Trichuris suis ova, a potential immunomodulator, is safe in adults and children allergic to peanut or tree nuts.
- Trial name
- NCT01070498
- Testing
- Trichuris suis ova (TSO)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Beth Israel Deaconess Medical Center
Peanut Allergy
OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
This is a phase 1, multi-center, randomized, double-blind, placebo-controlled study in adult participants with peanut allergy. Participants will be randomized in a 3:1 ratio to receive either an escalating dose of INT301 or…
- Trial name
- NCT04603300
- Testing
- INT301
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Intrommune Therapeutics
Peanut Hypersensitivity
Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut
The purpose of this study is to develop a tool to better predict clinical allergy to peanut, so that those who are skin test positive but non allergic will not have to unnecessarily avoid peanut, and those with true allergy can…
- Trial name
- NCT00243555
- Testing
- allergy skin testing, venepuncture
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hamilton Health Sciences Corporation
Food Allergy
Mixed Tree Nut Food Challenges
The purpose of this prospective study is twofold: 1) to establish oral tolerance to selected tree nuts and to examine potential predictors of oral tolerance and 2) to determine the usefulness of mixed tree nut allergen food…
- Trial name
- NCT02070263
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Arkansas Children's Hospital Research Institute
Allergy, Peanut
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind…
- Trial name
- VITESSE (NCT05741476)
- Testing
- DBV712
- Where
- 87 sites in United States, Australia and 7 more
- Volunteers
- 600 people
- Sponsor
- DBV Technologies
Food Hypersensitivity
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of…
- Trial name
- DEVIL (NCT00932828)
- Testing
- Peanut oral immunotherapy
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA).
- Trial name
- PROTECT (NCT05476497)
- Testing
- VLP Peanut
- Where
- 10 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Peanut Allergies, Tree Nut Allergies
Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies
Food allergies are now a major problem. These experiments involve getting blood from people with food allergies and from people without food allergies.
- Conditions
- Peanut Allergies, Tree Nut Allergies, Other Food Allergies
- Trial name
- NCT02192866
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Peanut Allergy
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
This study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.
- Trial name
- NCT01451450
- Testing
- QGE031
- Sponsor
- Novartis Pharmaceuticals
Peanut Allergy
Early Peanut Introduction: Translation to Clinical Practice
The recent finding that early introduction of peanut can prevent ~70-90% of peanut allergy is a major step towards prevention of food allergy.
- Trial name
- EPI (NCT03019328)
- Testing
- Peanut in diet
- Where
- 2 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Food Allergy
The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults
In Finland, the estimated prevalence of physician-diagnosed food allergy in 1-4 year old children is 9%, and the most common allergen is milk. The overall food allergy has been reported to be 3.7%.
- Trial name
- NCT01822353
- Testing
- Dietary supplement
- Where
- Finland
- Volunteers
- 23 people
- Sponsor
- Helsinki University Central Hospital